Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings

Pfizer

Status: Completed

Conditions: Psoriasis

Treatments: Drug: etanercept (Enbrel®)

Study type: Observational

Funder types: Industry

Identifiers

NCT00708708

0881X1-4499

B1801081 (Other Identifier)

Details and patient eligibility

About

This prospective observational cohort study will assess the average duration of the drug free interval between etanercept treatment cycles in usual care settings in Germany.

Full description

Non-interventional study: subjects to be selected according to the usual clinical practice of their physician

Enrollment: 926 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with moderate to severe plaque psoriasis on etanercept treatment according to the Summary of Product Characteristics (SmPC), and applicable local guidelines
• Subjects for whom the decision has already been made to initiate treatment with etanercept

Exclusion criteria

• Sepsis or risk of sepsis
• Current or recent infections, including chronic or localized, e.g. tuberculosis (TB) infection
• Vaccination with live vaccine in last 4 weeks, or expected to require such vaccination during the course of the study
• Pre-existing or recent onset CNS demyelinating disease.
• Class III or IV congestive heart failure as defined by the New York Heart Association classification or uncompensated congestive heart failure.
• Previous or ongoing treatment with etanercept
• Participation in other clinical or observational studies.
• Patients with psoriatic arthritis requiring continuous etanercept treatment.

Trial design

926 participants in 1 patient group

A

Description:

Patients with moderate to severe plaque psoriasis

Treatment:

Drug: etanercept (Enbrel®)